Neuro-oncology SACT Regimens

The information contained in these regimens is a statement of consensus of NCCP and ISMO or IHS professionals regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult these documents is expected to use independent medical judgement in the context of individual clinical circumstances to determine any patient's care or treatment. The treatment regimen to be used should take into account factors such as histology, molecular pathology, age, performance status, co-morbidities and the patient’s preference. Each treatment regimen has advantages and disadvantages, and there may be more than one good option.  In addition, treatment choices can change over time as more evidence becomes available.Use of these documents is the responsibility of the prescribing clinician and is subject to the terms of use.

Please email any comments or feedback on these regimens to

For information on open clinical trials please refer to the Cancer Trials Ireland website here and also to basket trials here.

Neuro-oncology Regimens

Regimen Name Indication

Bevacizumab 5mg/kg Monotherapy – 14 Day



Treatment of recurrent malignant glioblastoma multiforme

Procarbazine Lomustine and VinCRIStine (PCV) Therapy



Adjuvant treatment of Grade II glioma administered after radiotherapy.


Palliative treatment for recurrent high grade gliomas.

Procarbazine, Lomustine and VinCRIStine (PCV) Therapy – 56 days



Adjuvant treatment of Grade II glioma administered after radiotherapy.

Lomustine and Bevacizumab 5mg/kg Therapy



For the treatment of recurrent malignant glioblastoma.

Temozolomide with Radiotherapy (RT) and Adjuvant Therapy



Adult patients with newly-diagnosed glioblastoma multiforme concomitantly with radiotherapy (RT) followed by adjuvant treatment commencing 4 weeks after completion of chemoradiation

Temozolomide with Radiotherapy (RT) and Adjuvant Therapy-Patients greater than 65 years



Adult patients greater than 65 years with newly-diagnosed glioblastoma multiforme not suitable for the standard radiotherapy regimen in combination with temozolomide ii

Temozolomide Recurrent Therapy



Adult patients with Grade III or IV malignant glioma, such as glioblastoma multiforme or anaplastic astrocytoma, showing recurrence or progression after standard therapy.